You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,835,473


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,835,473
Title:Methods and compositions for treating cancer
Abstract: The present invention provides methods of treating cancer using 2-amino-6-trifluoromethoxybenzothiazole (riluzole). In one aspect, the present invention provides methods of reducing cancer cell growth. In another aspect, the present invention provides a method of inducing apoptosis in a cancer cell. In another aspect, the present invention provides a method of reducing the growth of a glutamate-releasing tumor.
Inventor(s): Goydos; James S. (East Brunswick, NJ), Chen; Suzie (Highland Park, NJ)
Assignee: Rutgers, The State University of New Jersey (New Brunswick, NJ)
Application Number:12/560,119
Patent Claims:1. A method of treating breast cancer in a patient diagnosed with a breast cancer characterized by glutamate release or a breast cancer expressing glutamate receptor, metabotropic 1 (GRM1), said method comprising administering to said patient an amount of 2-amino-6-trifluoromethoxybenzothiazole (riluzole) effective to reduce breast cancer cell growth, proliferation or metastasis.

2. The method of claim 1, wherein the breast cancer expresses glutamate receptor, metabotropic 1 (GRM1).

3. The method of claim 1, further comprising administering an anti-proliferative agent, a chemotherapeutic agent, a B-raf inhibitor, a PI3K inhibitor, an anti-apoptosis inhibitor, a benzoquinone ansamycin antibiotic, an anti-angiogenesis agent, or a combination thereof.

4. The method of claim 3, wherein said chemotherapeutic agent is selected from the group consisting of 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide (temozolomide); 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine); platinum, diammine[1,1-cyclobutane-dicarboxylato (2-)-0,0']-,(SP-4-2) (carboplatin); and 5.beta.,20-Epoxy-1,2.alpha., 4,7.beta.,10.beta.,13.alpha.-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)--N-benzoyl-3-phenylisoserine (paclitaxel).

5. The method of claim 3, wherein said B-raf inhibitor is 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyri- dine-2-carboxamide 4-methylbenzenesulfonate (sorafenib).

6. The method of claim 3, wherein said anti-apoptosis inhibitor is a Bcl-2 inhibitor.

7. The method of claim 3, wherein said benzoquinone ansamycin antibiotic is geldanamycin or 17-N-allylamino-17-demethoxygeldanamycin.

8. The method of claim 3, wherein said anti-angiogenisis agent is bevacizumab.

9. A method for reducing growth of a glutamate-releasing or GRM1-expressing breast cancer tumor in a subject in need thereof, comprising administering to a subject having a glutamate-releasing or GRM1-expressing breast cancer tumor an amount of 2-amino-6-trifluoromethoxybenzothiazole (riluzole) effective to reduce one or more of tumor cell growth, proliferation, and metastasis.

10. The method of claim 9, wherein the glutamate-releasing breast cancer tumor expresses GRM1.

11. The method of claim 9, further comprising administering an anti-proliferative agent, a chemotherapeutic agent, a B-raf inhibitor, a PI3K inhibitor, an anti-apoptosis inhibitor, a benzoquinone ansamycin antibiotic, an anti-angiogenesis agent, or a combination thereof.

12. The method of claim 11, wherein said chemotherapeutic agent is selected from the group consisting of 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide (temozolomide); 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine); platinum, diammine[1,1-cyclobutane-dicarboxylato (2-)-0,0']-,(SP-4-2) (carboplatin); and 5.beta.,20-Epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-hexahydroxytax-1- 1-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)--N-benzoyl-3-phenylisoserine (paclitaxel).

13. The method of claim 11, wherein said B-raf inhibitor is 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyri- dine-2-carboxamide 4-methylbenzenesulfonate (sorafenib).

14. The method of claim 11, wherein said anti-apoptosis inhibitor is a Bcl-2 inhibitor.

15. The method of claim 11, wherein said benzoquinone ansamycin antibiotic is geldanamycin or 17-N-allylamino-17-demethoxygeldanamycin.

16. The method of claim 11, wherein said anti-angiogenesis agent is bevacizumab.

17. The method of claim 9, wherein the riluzole is administered prior to surgical excision of at least a portion of the tumor.

18. The method of claim 9, wherein the riluzole is administered following surgical excision of at least a portion of the tumor.

19. The method of claim 9, wherein the riluzole is administered in a chronic dose.

20. The method of claim 9, wherein the riluzole is administered orally, intravenously, or intraperitoneally.

21. A method of treating a glutamate-releasing GRM1-expressing breast cancer in a patient diagnosed with said cancer, comprising administering to said subject an amount of 2-amino-6-trifluoromethoxybenzothiazole (riluzole) effective to reduce the breast cancer cell growth, proliferation or metastasis.

22. A method of treating a glutamate-releasing breast cancer in a patient diagnosed with said cancer, comprising administering to said patient an amount of 2-amino-6-trifluoromethoxybenzothiazole (riluzole) effective to reduce one or more of cancer cell growth, proliferation, and metastasis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.